R&D spending: $49,676,000
Percentage of revenues: 27.4%
2019 overall revenue ranking: 87
Glaukos’s research and development expenses went toward new product development projects, pre-clinical studies, IDE studies and other clinical trials.
The company said in its SEC annual report filing that it plans to expand pharmaceutical and IOP sensor development efforts, as well as clinical trials.